20s Proteasome - Pipeline Review, H1 2018

  • ID: 4518491
  • Report
  • 63 pages
  • Global Markets Direct
1 of 5
20s Proteasome - Pipeline Review, H1 2018

Summary:

According to the recently published report '20s Proteasome - Pipeline Review, H1 2018'; 20s Proteasome pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.

20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex.

The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides.

The report '20s Proteasome - Pipeline Review, H1 2018' outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively.

Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Non Malignant Disorders and Women's Health which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Gynecological Cancer, Waldenstrom Macroglobulinemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyloidosis, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometriosis, Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Kidney Transplant Rejection, Lymphoma, Malignant Glioma, Mantle Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Renal Cell Carcinoma, Skin Cancer, Small-Cell Lung Cancer, Solid Tumor, T-Cell Lymphomas, Tuberculosis and Uterine Leiomyoma (Uterine Fibroids).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
  • The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
  • The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 20s Proteasome targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 20s Proteasome
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Report Coverage

20s Proteasome - Overview

20s Proteasome - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

20s Proteasome - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

20s Proteasome - Companies Involved in Therapeutics Development

Amgen Inc

Celgene Corp

20s Proteasome - Drug Profiles

carfilzomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

marizomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oprozomib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit 20s Proteasome for Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPE-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPEA-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPEA-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

20s Proteasome - Dormant Products

20s Proteasome - Product Development Milestones

Featured News & Press Releases

Jan 30, 2018: Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS (carfilzomib) Label

Jan 17, 2018: FDA Approves Addition Of Overall Survival Data To KYPROLIS (carfilzomib) Label

Jan 17, 2018: Overall Survival Analysis From KYPROLIS (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology

Dec 28, 2017: Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients

Dec 11, 2017: KYPROLIS (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial

Oct 23, 2017: Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients

Aug 30, 2017: FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS (Carfilzomib) Label

Aug 30, 2017: Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma

Aug 23, 2017: Overall Survival Analysis From KYPROLIS Phase 3 Endeavor Trial Published In The Lancet Oncology

Aug 08, 2017: Scottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS (carfilzomib), in Combination with Dexamethasone, for use at First Relapse

Aug 07, 2017: Amgen’s Kyprolis accepted for use in NHS Scotland

Jul 24, 2017: Novocure Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune as Adjuvant Therapy in Patients with Glioblastoma

Jul 19, 2017: NICE approves more tolerable treatment for blood cancer

Jul 14, 2017: Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS (Carfilzomib) Label

Jul 12, 2017: Second Phase 3 Study Shows KYPROLIS (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Celgene Corp, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Amgen Inc
  • Celgene Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll